Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH.
Sokolova AO, et al.
Prostate. 2021 Dec;81(16):1382-1389. doi: 10.1002/pros.24236. Epub 2021 Sep 13.
Prostate. 2021.
PMID: 34516663
Free PMC article.
METHODS: This is an international multicenter retrospective matched cohort study of men with prostate cancer harboring gATM or gBRCA2. PSA(50) response ( 50% decline in prostate-specific antigen) was compared using Fisher's exact test. ...Men wi …
METHODS: This is an international multicenter retrospective matched cohort study of men with prostate cancer harboring gATM or …